ImmunityBio (IBRX) Gains Retail Attention After DCF Analysis Suggests Undervaluation

IBRX ranked third in retail ticker discussion on January 22, with a sentiment score of 0.55.
A DCF analysis on r/Shortsqueeze estimated a fair value of $20.93, suggesting the stock is undervalued.
The analysis cited recent FDA and Saudi approvals for Anktiva as key catalysts.

ImmunityBio (

$IBRX) emerged as a top retail discussion ticker on January 22, 2026, ranking third overall with a sentiment score of 0.55. The conversation was largely driven by a detailed valuation post on r/Shortsqueeze that argued the stock is significantly undervalued.

Reddit Discussion Highlights

The most prominent post came from r/Shortsqueeze, where a user shared a discounted cash flow (DCF) analysis of

$IBRX. The analysis concluded with a fair value estimate of $20.93 per share, implying the stock was trading at a discount. The post garnered 42 upvotes and 3 comments, reflecting strong engagement relative to the ticker's overall discussion volume.

The DCF model incorporated recent regulatory milestones, including FDA and Saudi approvals for Anktiva, ImmunityBio's lead immunotherapy candidate. These approvals were cited as key drivers of future revenue, supporting the bullish valuation.

Broader Retail Sentiment

Across Reddit,

$IBRX appeared in 5 posts with 58 comments and 12 upvotes. The average sentiment of 0.55 leaned bullish, consistent with the positive tone of the DCF analysis. The ticker's rank improved by one position from the previous day, indicating growing interest.

The broader r/stocks community also showed elevated activity, with 45 posts and 2,426 comments on the day, though specific

$IBRX mentions were concentrated in the r/Shortsqueeze post.

IBRX

Key Catalysts

The DCF analysis highlighted two major regulatory approvals for Anktiva: the FDA approval and a recent approval in Saudi Arabia. These milestones are seen as validating the drug's commercial potential and expanding its addressable market. The author argued that the market has not fully priced in these developments, leaving room for upside.

No same-day news articles were available for

$IBRX, making the Reddit analysis the primary driver of retail discussion.

Subscribe to Tendie.bot for more market recaps.